Day: May 26, 2020

SUNNYVALE, Calif., May 26, 2020 (GLOBE NEWSWIRE) — Ooma, Inc. (NYSE: OOMA), a smart communications platform for businesses and consumers, today released financial results for the first quarter fiscal 2021 ended April 30, 2020.First Quarter Fiscal 2021 Financial Highlights:Revenue: Total revenue was $40.3 million, up 19% year-over-year. Subscription and services revenue increased to $37.6 million and was 93% of total revenue, driven by 22% year-over-year growth in combined Ooma Business and Ooma Residential services.Net Income/Loss: GAAP net loss was $1.1 million, or $0.05 per basic and diluted share, compared to GAAP net loss of $4.7 million, or $0.23 per basic and diluted share, in the first quarter fiscal 2020. Non-GAAP net income was $2.4 million, or $0.11 per diluted share, compared to a non-GAAP net loss of $0.8 million, or...

CORONA, Calif., May 26, 2020 (GLOBE NEWSWIRE) — Monster Beverage Corporation (NASDAQ:MNST) announced today that the Company will host a live webcast of its Annual Meeting of Stockholders on Wednesday, June 3, 2020. This year, in light of the public health impact of the novel coronavirus (COVID-19) pandemic and the protocols that federal, state and local governments have imposed, the Company is conducting its Annual Meeting of Stockholders exclusively as a virtual meeting via live webcast. The live webcast will start at 2:30 p.m. Pacific Time.A live webcast of the Annual Meeting can be accessed through www.virtualshareholdermeeting.com/MNST2020. For those who are not able to listen to the live webcast, the event will be archived for approximately one year on the Company’s website at www.monsterbevcorp.com, under the “Events &...

CALGARY, Alberta, May 26, 2020 (GLOBE NEWSWIRE) — Founders Advantage Capital Corp. (TSX-V: FCF) (“FAC” or the “Corporation”) is pleased to report its financial results for the three months ended March 31, 2020 (“Q1-2020”).  For complete information, readers should refer to the consolidated financial statements and management discussion and analysis which are available on SEDAR at www.sedar.com and on the Corporation’s website at www.advantagecapital.ca.  All amounts are presented in Canadian dollars unless otherwise stated. 

READING, Pa., May 26, 2020 (GLOBE NEWSWIRE) — EnerSys (NYSE: ENS) the global leader in stored energy solutions for industrial applications announced today that it plans to release its fourth quarter and full year fiscal 2020 results on June 1, 2020. The Company will host a conference call to discuss its fourth quarter and full year fiscal 2020 financial results on June 2, 2020, and to provide an overview of the business. The call will conclude with a question and answer session.The call, scheduled for Tuesday, June 2, 2020 beginning at 9:00 a.m. Eastern Time, will be hosted by David M. Shaffer, Chief Executive Officer, and Michael J. Schmidtlein, Chief Financial Officer.A live webcast of the conference call will be available on the Company’s website at http://www.enersys.com under the “Investor Relations” link. Presentation...

VANCOUVER and MINNEAPOLIS, May 26, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today 1) an offering (“Offering”) of convertible notes (“2020 Notes”) and warrants (“2020 Warrants”) to Strul Medical Group for gross proceeds of up to US$5.0 Million; 2) all of the Company’s remaining 2017 Notes have been fully repaid or converted (“2017 Note Settlement”); 3) Neovasc entered into a settlement agreement with certain holders (the “2017 Holders”) of the 2017 Notes whereby the Company will issue warrants (“Settlement Warrants”) to such holders and 4) Neovasc entered...

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will present a company overview at the upcoming Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m. ET. A live webcast of the presentation will be available under “Events and Presentations” in the Investors & Media section of the company’s website, www.prevailtherapeutics.com. The webcast will be archived for 90 days following the event.About Prevail TherapeuticsPrevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing...

DURHAM, N.C., May 26, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced its participation in the following upcoming investor conferences:Jefferies Virtual Healthcare ConferenceDate: Wednesday, June 3, 2020Time: 9:30 – 9:55 AM ETSpeaker: Matt Kane, Chief Executive Officer and co-founder Goldman Sachs 41st Annual Global Healthcare ConferenceDate: Thursday, June 11, 2020Time: 8:50 – 9:30 AM ETSpeaker: Matt Kane, Chief Executive Officer and co-founderLive webcasts of each presentation will be accessible on the Company’s website, www.PrecisionBiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for 30 days following...

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on Tuesday, June 2, 2020, at 1:00 p.m. ET.A live audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary...

Nominates Three Medical Device Industry Veterans – Lonny Carpenter, David Floyd and James Hogan – for Election to the Board of Directors

Regulated information — Inside informationMay 26, 2020Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced a global offering of $500 million (approximately €458.3 million) of ordinary shares, which may be represented by American Depository Shares (“ADSs”). The global offering will be comprised of an offering of ordinary shares represented by ADSs in the United States and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area. Each of the ADSs represents the right to receive one ordinary share, nominal value of €0.10...